Search results
Showing 1576 to 1590 of 8900 results
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab (Gazyvaro) for untreated chronic lymphocytic leukaemia in adults.
Show all sections
NICE is unable to make a recommendation on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in people 12 years and over. This is because Roche did not provide a complete evidence submission.
Show all sections
Sections for TA1118
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)
Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Tofacitinib for treating active ankylosing spondylitis (TA920)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.
Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for treating active non-radiographic axial spondyloarthritis.
Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
Upadacitinib for treating active ankylosing spondylitis (TA829)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
NICE is unable to make a recommendation on depemokimab (Exdensur) for treating chronic rhinosinusitis with nasal polyps in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1123